Baseline Vitamin B12 and Folate Levels Do Not Predict Improvement in Depression After a Single Infusion of Ketamine

Abstract

Introduction: Deficiencies in both vitamin B12 and folate have been associated with depression. Recently, higher baseline vitamin B12 levels were observed in individuals with bipolar depression who responded to the antidepressant ketamine at 7 days post-infusion. This study sought to ­replicate this result by correlating peripheral vitamin levels with ketamine’s antidepressant efficacy in bipolar depression and major depressive disorder (MDD).

Methods: Baseline vitamin B12 and folate levels were obtained in 49 inpatients with treatment-resistant MDD and 34 inpatients with treatment-resistant bipolar depression currently experiencing a major depressive episode. All subjects received a single intravenous ketamine infusion. Post-hoc Pearson correlations were performed between baseline vitamin B12 and folate levels, as well as antidepressant response assessed by percent change in Hamilton Depression Rating Scale (HDRS) scores from baseline to 230 min, 1 day, and 7 days post-infusion.

Results: No significant correlation was observed between baseline vitamin B12 or folate and percent change in HDRS for any of the 3 time points in either MDD or bipolar depression.

Discussion: Ketamine’s antidepressant efficacy may occur independently of baseline peripheral vitamin levels.

Key words

vitamin B12 - folate - ketamine - bipolar depression - major depressive disorder

• References

• 1 Niciu MJ, Henter ID, Luckenbaugh DA et al. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Ann Rev Pharmacol Toxicol 2014; 54: 119-139
• 2 Aan Het Rot M, Zarate Jr. CA, Charney Jr. DS et al. Ketamine for depression: where do we go from here?. Biol Psychiatry 2012; 72: 537-547
• 3 Diazgranados N, Ibrahim L, Brutsche NE et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793-802
• 4 Diazgranados N, Ibrahim LA, Brutsche NE et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010; 71: 1605-1611
• 5 Murrough JW, Perez AM, Pillemer S et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013; 74: 250-256
• 6 Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol 2005; 19: 59-65
• 7 Shorvon SD, Carney MW, Chanarin I et al. The neuropsychiatry of megaloblastic anaemia. Br Med J 1980; 281: 1036-1038
• 8 Tiemeier H, van Tuijl HR, Hofman A et al. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002; 159: 2099-2101
• 9 Hintikka J, Tolmunen T, Tanskanen A et al. High vitamin B12 level and good treatment outcome may be associated in major depressive disorder. BMC Psychiatry 2003; 3: 17
• 10 Permoda-Osip A, Dorszewska J, Bartkowska-Sniatkowska A et al. Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression. Pharmacopsychiatry 2013; 46: 227-228
• 11 Niciu MJ, Luckenbaugh DA, Ionescu DF et al. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry 2014; in press
• 12 Luckenbaugh DA, Niciu MJ, Ionescu DF et al. Do the dissociative side effects of ketamine mediate its antidepressant effects?. J Affect Disord 2014; 159: 56-61
• 13 First MB, Spitzer RL, Gibbon M et al. Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition (SCIDI/P. Version 2.0): Biometric Research/New York State Psychiatric Institute 1995;
• 14 Zarate Jr. CA, Brutsche NE, Ibrahim L et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012; 71: 939-946
• 15 Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001; 62 (Suppl. 16) 10-17
• 16 Hochberg Y. A sharper bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-802
• 17 Zarate Jr. CA, Singh JB, Carlson PJ et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864
• 18 Ibrahim L, Diazgranados N, Franco-Chaves J et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012; 37: 1526-1533
• 19 Papoulis A. Probability and Statistics: Prentice-Hall International Editions 1990;
• 20 Murrough JW, Iosifescu DV, Chang LC et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013; 170: 1134-1142
• 21 Berlanga C, Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 2006; 95: 119-123
• 22 Kornstein SG, Schatzberg AF, Thase ME et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157: 1445-1452
• 23 Martenyi F, Dossenbach M, Mraz K et al. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 2001; 11: 227-232
• 24 Furey ML, Khanna A, Hoffman EM et al. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology 2010; 35: 2479-2488
• 25 Niciu MJ, Ionescu DF, Richards EM et al. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm. 2013